Real-world outcomes of cytokine-modulating treatment strategies in severe COVID-19 pneumonia: A multicenter observational cohort

During the coronavirus disease 2019 (COVID-19) pandemic, different immunomodulatory strategies were adopted in routine practice. However, treatment selection often depends on illness severity and resource availability, and interpreting real-world outcomes is challenging. We aimed to describe clinical outcomes according to cytokine-modulating treatment strategies in severe COVID-19 pneumonia. We conducted a multicenter ambispective observational cohort study including adults with severe COVID-19 pneumonia treated with either tocilizumab or hemoperfusion between January 2020 and December 2021. Treatment allocation was determined by treating physicians under real-world conditions. The primary outcome was 30-day all-cause mortality. Multivariable Cox regression was used to explore factors associated with mortality. Ninety-two patients were included (tocilizumab n = 67; hemoperfusion n = 25). Patients receiving hemoperfusion had substantially greater baseline illness severity. C-reactive protein declined after treatment in both groups. Crude 30-day mortality was 22.4% in the tocilizumab group and 60.0% in the hemoperfusion group. Treatment modality was not statistically associated with mortality after adjustment (adjusted hazard ratio, 0.70; 95% confidence interval, 0.28-1.72), whereas a Sequential Organ Failure Assessment (SOFA) score ≥3 and higher baseline interleukin-6 (IL-6) were associated with mortality. Among patients with lower illness severity (SOFA <3), tocilizumab showed a nonsignificant trend toward improved survival. In this real-world cohort, baseline disease severity rather than treatment modality was the dominant determinant of outcome. Tocilizumab was more commonly used at earlier disease stages, whereas hemoperfusion was preferred in patients with clinical deterioration. These findings highlight the importance of patient selection when interpreting treatment outcomes in observational studies of severe COVID-19.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-20
DOI
https://doi.org/10.1097/md.0000000000051604
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world outcomes of cytokine-modulating treatment strategies in severe COVID-19 pneumonia: A multicenter observational cohort

Kulapong Jayanama, Ittikorn Spanuchart, Lerkiat Wicharit, Supawadee Suppadungsuk et al.
Medicine
COVID-19 Clinical Research Studies
article

Real-world outcomes of cytokine-modulating treatment strategies in severe COVID-19 pneumonia: A multicenter observational cohort

Kulapong Jayanama, Ittikorn Spanuchart, Lerkiat Wicharit, Supawadee Suppadungsuk, Adisorn Pathumarak, Kanin Thammavaranucupt, Suwit Wankaew
article en

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, different immunomodulatory strategies were adopted in routine practice. However, treatment selection often depends on illness severity and resource availability, and interpreting real-world outcomes is challenging. We aimed to describe clinical outcomes according to cytokine-modulating treatment strategies in severe COVID-19 pneumonia. We conducted a multicenter ambispective observational cohort study including adults with severe COVID-19 pneumonia treated with either tocilizumab or hemoperfusion between January 2020 and December 2021. Treatment allocation was determined by treating physicians under real-world conditions. The primary outcome was 30-day all-cause mortality. Multivariable Cox regression was used to explore factors associated with mortality. Ninety-two patients were included (tocilizumab n = 67; hemoperfusion n = 25). Patients receiving hemoperfusion had substantially greater baseline illness severity. C-reactive protein declined after treatment in both groups. Crude 30-day mortality was 22.4% in the tocilizumab group and 60.0% in the hemoperfusion group. Treatment modality was not statistically associated with mortality after adjustment (adjusted hazard ratio, 0.70; 95% confidence interval, 0.28-1.72), whereas a Sequential Organ Failure Assessment (SOFA) score ≥3 and higher baseline interleukin-6 (IL-6) were associated with mortality. Among patients with lower illness severity (SOFA <3), tocilizumab showed a nonsignificant trend toward improved survival. In this real-world cohort, baseline disease severity rather than treatment modality was the dominant determinant of outcome. Tocilizumab was more commonly used at earlier disease stages, whereas hemoperfusion was preferred in patients with clinical deterioration. These findings highlight the importance of patient selection when interpreting treatment outcomes in observational studies of severe COVID-19.

MedicineVol. 105(47)
Mahidol University (TH), University of Michigan (US), Michigan Medicine (US), Ramathibodi Hospital (TH), Ramathibodi Chakri Naruebodindra Hospital (TH), Boromarajonani College of Nursing, Nakhon Ratchasima (TH)
Good health and well-being
COVID-19 Clinical Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon